LGND ▼ -0.0% - Ligand Pharmaceuticals Incorporated $LGND Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® Ligand Pharmaceuticals (LGND) showed little price movement today following an announcement that Sydnexis entered into a royalty agreement with the company for Ryjunea®, its commercial-stage therapeutic candidate. The agreement establishes royalty obligations tied to Ryjunea® sales, which could represent a future revenue stream for Ligand once the product generates commercial revenue. 22-SEP-2026 09:02 AM ET